Consultation on the Implementation of Good Distribution Practice (GDP) for Pharmaceutical ProductsHome > What's New > Consultation on the Implementation of Good Distribution Practice (GDP) for Pharmaceutical Products Consultation on the Implementation of Good Distribution Practice (GDP) for Pharmaceutical ProductsIn support of enhancing supply chain integrity and aligning with internationally recognised standards and practices, the Pharmacy and Poisons Board of Hong Kong (the “Board”) endorsed the proposal to implement Good Distribution Practice (“GDP”) in Hong Kong by adopting the Pharmaceutical Inspection Co-operation Scheme Guide to Good Distribution Practice. The proposal will be implemented through the imposition of additional application requirements or licensing conditions on manufacturers and wholesale dealers, tentatively start off with new applicants in Q3 2026 as licensing requirements and extend to relevant existing licensees in Q3 2028.
In this connection, the following draft documents for implementation of GDP have been prepared for inviting comments and views from the public. Guidance Documents:
If the public have any comments on the above draft documents, please send them to the Drug Office of the Department of Health on or before 31 May 2026 by any of the following means:
For further information about the Implementation of GDP for Pharmaceutical Products, please visit the website of the Drug Office of the Department of Health at |